Mood Modifying Drug Market
- ID: 2422080
- March 2012
- 65 Pages
- The Pharmaceutical Strategist
The market for mood modifying drugs, those ethical pharmaceutical drugs that treat both anxiety and depression, has been declining by an average (-4%) per year over the past five years.
The main reasons for decline are both intensive generic competition coupled with mismanagement, on the part of marketing directors and strategists at the helm of CNS business unit in leading multinational pharmaceutical companies, when it comes to brand and lifecycle management strategies of their branded assets.
The Pharmaceutical Strategist, a leading long range scenario planning think tank for the life science industry has been calling for a change in the way mood modifying drugs are being branded, positioned and marketed for over a decade.
This latest edition of its highly praised Mood Modifying Drug Market Report is completely revised and takes into account the recent recommendations of DSM-5, which was published, as a draft, in December 2012.
If you are a top executive in either a branded or generic pharmaceutical multinational that carries a line of CNS drugs targeted at the areas of depression or anxiety, this report will become an indispensable reference tool during your next strategy meeting when trying to defend against the severe budget cuts that are inevitably coming to both your R&D and Promotional spending budgets.
The Pharmaceutical Strategist's Mood Modifying Drug Market report is targeted at the senior decision maker and takes a helicopter view of the market with a time span stretching from the good old days of the 70s to the many interesting scenarios that might be unfolding in the medium range future.
Don't miss out on this top-level insight loop. Don't miss out on this timeless classic.
ii Preface to First edition
iii Preface to Fifth Edition
iv Scenario Planning
1. Mood & Anxiety Disorders
1.1 Mood Disorders
1.1.1 Unipolar Depression
1.1.2 Bipolar Depression
1.2 Anxiety Disorders
1.2.1 Generalized Anxiety Disorder (GAD)
1.2.3 Panic Disorder
1.2.4 Obsessive Compulsive Disorder
1.3 Coincidence of Mood & Anxiety Disorders
1.4 Unitary Theory of Mood & Anxiety Disorders
1.5 DSM-5 & The Need for Still Newer Classifications
2. Non-Pharmacological Management of Mood & Anxiety Disorders
2.1 Inter & Intra Personal Theories
2.1.1 The Psychodynamic Model
2.1.2 The Cognitive Model
2.1.3 The Learned-Helplessness Model
2.2.1 Cognitive Behavioral Psychotherapy
2.2.2 Interpersonal Psychotherapy
2.3 ElectroConvulsive Therapy (ECT)
2.4 Deep Brain Stimulation
2.5 Other Treatment Modalities
2.5.3 Sleep Deprivation
2.5.4 Sex Therapy
3. Pharmacological Management of Mood & Anxiety Disorders
3.1 Cellular Organization of the Brain
3.2 Biological Theories of Mood & Anxiety Disorders
3.2.1 Genetic Underpinning of Mood & Anxiety Disorders
3.2.2 The Neurotransmitters hypothesis
3.3 Anxiolytic (Sedatives & Hypnotics)
3.3.3 Non-Benzodiazine Anxiolytics
3.4.1 Tricyclic Antidepressants
3.4.2 Monoamine Oxidase Inhibitors (MAO)
3.4.3 Selective Serotonin Re-Uptake Inhibitors (SSRIs)
3.4.4 Serotonin–Noradrenaline Re-Uptake Inhibitors (SNRIs)
3.4.5 Nicotinic Acetylcholine Receptors Antagonists
3.4.6 Special K
4. Mood Modifying Drug Market
4.1 Anxiolytic Era
4.2 Antidepressants Era
4.3 Current Mood Modifying Drug Market
4.4 Leading Companies & Their Brands
4.4.1 Eli Lilly
4.4.4 Forest Laboratories
4.5 Geographical Segmentation
4.5.1 US Mood Modifying Drug Market
4.5.2 EU Mood Modifying Drug Market
4.5.3 Japan Mood Modifying Drug Market
4.5.4 Emerging Mood Modifying Drug Market
5. Forces Driving the Market
5.1 Unmet Need
5.2 Shifts in Market Dynamics
5.3 Unification of Markets
5.4 Impact of the Information Society
5.5 Novel Technologies
6. Strategies for Success
6.1 Optimizing the Commercial Potential
6.2 Patents, Generics & Life Cycle Management
6.3 Disease Management Strategies
6.4 Health Management Strategies
6.5 Evolutionary Stable Strategies
6.6 Market Forecast
7. Pharmaceutical Strategist Scenarios
7.1 As Good As It Gets
7.2 Designer Brains
7.3 Brave New World
List of Tables & Figures
1. Global Mood Modifying Drug Market
2. Top Five Leading Mood Modifying Drug Brands
3. Global Market for Tranquilizers
4. Global Market for Antidepressants
5. US Mood Modifying Drug Market
6. European Mood Modifying Drug Market
7. Japanese Mood Modifying Drug Market
8. Emerging Mood Modifying Drug Market
9. Leading Companies Market Shares
10. Eli Lilly Mood Modifying Drug Portfolio
11. Pfizer Mood Modifying Drug Portfolio
12. GSK Mood Modifying Drug Portfolio s
13. Forest Laboratories Mood Modifying Drug Portfolio
14. Lundbeck Mood Modifying Drug Portfolio
15. Mood Modifying Drug Market Forecast
2. Eli Lilly
3. Forest Laboratories
Mood Modifying Drugs Market
What we now know about the interaction of biology and experience tells us that the distinction between temperament and character is arbitrary and artificial. Inherited variation in neurochemical activity which used to determine dispositions to certain moods and learning styles are not destiny and can be changed by biochemical agents.
The neural chemistry with which we arrive to the world is inevitably modified by development, environment, life events and discrete medicine. Enduring personality changes can follow drug-induced changes of mood, coping behavior and learning styles.
As neuroscientists link fitness for different environmental challenges to the activity of specific neurotransmitters the question remains open; would mood modifying drugs act as a new evolutionary tool to help people cope better with stressful environment?
Psychiatric distress is a warning signal that, at some level, a change is needed in order to build or restore a healthy balance to a person's life. Medications that can change perception and allow adaptation to a challenging environment can be used as evolutionary agents that enable the individual sculpt the personality that he or she thinks is most suited to their adaptation and, eventually, success.
Pharmaceutical companies have access to enabling technologies that allow them to offer designer personalities in a pill.
The $100 billion question is: Do they have the will?